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Abstract
Alzheimer’s Disease (AD) is an age-related disease with modifiable risk factors such as 
hypertension, hypercholesterolemia, obesity, and physical inactivity influencing the onset and 
progression. There is however, no direct evidence that reducing these risk factors prevents or slows 
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AD. The Risk Reduction for Alzheimer’s Disease (rrAD) trial is designed to study the independent 
and combined effects of intensive pharmacological control of blood pressure and cholesterol and 
exercise training on neurocognitive function. Six hundred and forty cognitively normal older 
adults age 60 to 85 years with hypertension and increased risk for dementia will be enrolled. 
Participants are randomized into one of four intervention group for two years: usual care, Intensive 
Reduction of Vascular Risk factors (IRVR) with blood pressure and cholesterol reduction, exercise 
training (EX), and IRVR+EX. Neurocognitive function is measured at baseline, 6, 12, 18, and 24 
months; brain MRIs are obtained at baseline and 24 months. We hypothesize that both IRVR and 
EX will improve global cognitive function, while IRVR+EX will provide a greater benefit than 
either IRVR or EX alone. We also hypothesize that IRVR and EX will slow brain atrophy, improve 
brain structural and functional connectivity, and improve brain perfusion. Finally, we will explore 
the mechanisms by which study interventions impact neurocognition and brain. If rrAD 
interventions are shown to be safe, practical, and successful, our study will have a significant 
impact on reducing the risks of AD in older adults.
Keywords
Alzheimer’s Disease; Reduction of Vascular Risk factors; Exercise; Cognition; Brain structure
1. Introduction
1.1. Alzheimer’s Disease (AD) Risk and Cardiovascular Disease
Given the rapidly aging population [1], the prevention and treatment of age-related 
dementias, such as AD, presents as one of the most significant healthcare challenges of our 
times. Epidemiologic [2–4], laboratory, clinical [5–8], and translational studies, including 
genome-wide association studies [9–11], suggest that the onset and progression of age-
related dementias are multifactorial and influenced by modifiable risk factors [12–14]. With 
paucity of pharmacologic treatment for age-related dementias, identification of potentially 
modifiable risk (or protective) factors and an understanding of the effect of modifying these 
factors on incidence and progression of dementia is pivotal [14–16].
The presence of cardiovascular risk factors such as hypertension, hypercholesterolemia, and 
physical inactivity in mid-to-late life is associated with cognitive decline [17–19] and 
increased risk of all-cause dementia [20–22]. Older adults are particularly affected by these 
risk factors, with >80% of older adults having one or more risk factors [23–25]. These 
cardiovascular risk factors share common pathophysiologic mechanisms of neural-vascular 
interactions or coupling through which cerebral atherosclerosis, cerebral small vessel 
disease, disruption of the blood brain barrier, and brain hypoperfusion may occur, leading to 
neuronal damage or dysfunction [12, 26]. Furthermore, hypertension and 
hypercholesterolemia may affect brain amyloid-Beta (Aβ) and tau clearance through brain 
lipid homeostasis and blood flow regulation, further increasing AD risk [27–30].
The treatment of hypertension (HTN) and hypercholesterolemia for prevention of cognitive 
decline has been previously explored in clinical trials, but as secondary outcomes and with 
inconsistent findings [31, 32]. Aggregation of these data in recent meta-analyses and 
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systematic reviews show a reduction in all-cause dementia risk by 13% with treatment of 
HTN [33], and 29% with treatment of hypercholesterolemia [28]. Anti-hypertensives and 
statins have been shown to be safe in older adults and do not have deleterious effects on 
cognition [28, 32]. The benefits of intensive blood pressure (BP) and cholesterol lowering 
for preventing cardiovascular disease (CVD) and stroke have been demonstrated in a series 
of large clinical trials [34–36]. In addition to lowering risk of CVD and stroke, the recent 
Systolic Blood Pressure Intervention Trial (SPRINT) also showed lowering of combined 
clinical endpoints of incident mild cognitive impairment and dementia in the intensive BP 
control arm [37]. At present, the optimal goal of BP and blood lipid level reductions for 
dementia prevention remains uncertain. There is a strong suggestion from the current data 
that lowering of BP and/or treatment with statins may prevent or slow cognitive decline in 
older adults at risk for dementia [38].
1.2. Lifestyle interventions for cardiovascular risk
It is estimated that up to a half of AD cases may be related to physical inactivity, vascular 
and other potentially modifiable risk factors [39, 40]. Large population studies have 
indicated that the incidence of all-cause dementia may be decreasing, perhaps a reflection of 
multiple risk and protective factors, including higher educational levels, better control of 
cardiovascular risk factors and disease, and healthier lifestyles among older adults [41, 42]. 
An accumulating body of evidence from epidemiological, cross-sectional, and neuroimaging 
studies suggests that exercise is an important lifestlye strategy that is beneficial for cognitive 
health with aging. Prospective studies of non-demented older adults have shown a consistent 
relationship between higher levels of physical activity and reduced risk of dementia and 
cognitive decline, even after controlling for confounding factors such as education, vascular 
risk, and co-morbidities[43]. In cross-sectional studies, older adults who report greater 
engagement in physical activity earlier in life have a reduced risk of cognitive impairment 
and also perform better on tests of global cognitive function and executive function, 
compared to those who report low levels of activity[44, 45]. Neuroimaging studies have 
shown that older adults with higher fitness levels have reduced cerebral atrophy[46], higher 
grey matter density in pre-frontal and temporal regions[47], and larger hippocampal 
volumes[48]. These findings are encouraging and suggest that reducing modifiable risk 
factors may prevent or delay the onset of cognitive decline and AD [16, 49–51]. However, 
randomized controlled trials (RCTs) of the effects of exercise on cognitive in healthy older 
adults have had inconsistent findings. Although some meta-analyses reported improvements 
in cognitive outcomes in response to exercise training [52], a recent Cochrane Review that 
included twelve RCTs concluded that in healthy older adults, improving cardiorespiratory 
fitness does not result in improvements in cognitive function[53]. More recent RCTs of 
aerobic training using very similar protocols have also reported variable results[54, 55]. 
More exercise intervention studies, with longer follow-up periods, are needed to clarify the 
role of exercise as a preventive strategy for cognitive decline. Exercise alone, however, is 
unlikely to be fully effective in reducing cardiovascular risk factors once they have been 
established [35, 56]. It is also possible that exercise and/or reducing vascular risk factors 
each may have small to modest effects, but an integrated multimodal intervention of 
intensive pharmacological treatment and exercise may have additive and synergistic effects 
[12, 57–59]. The efficacy and effectiveness of an integrated strategy in the prevention and 
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treatment of CVD and other non-communicable chronic diseases are well established [35, 
56], but not well understood for prevention of cognitive decline or age-related dementia.
2. Methods
2.1. Summary/overall design
The objective of the rrAD study is to test the hypothesis that exercise combined with 
intensive pharmacological reduction of vascular risk factors (IRVR) over a period of 2 years 
provides greater benefits for neurocognitive function than either exercise or IRVR alone. The 
secondary objectives include assessment of improvements in domain specific neurocognitive 
function, patient-reported outcome measures of mental and physical health and health-
related quality of life, whole brain and hippocampal volume, global and regional brain 
perfusion, white matter lesions, brain white matter microstructural integrity, and neural 
network functional connectivity. Finally, the underlying mechanisms by which the study 
interventions impact brain structure and function will be explored by collecting blood 
biomarkers. rrAD is a multi-center, placebo controlled, randomized, trial with a 2 × 2 
factorial design. The study will enroll 640 cognitively normal older adults with hypertension 
and risk for dementia. Participants will be randomized to receive usual care (UC), intensive 
reduction of vascular risk factors (IRVR) with pharmacologic treatment of BP and 
cholesterol, moderate-to-vigorous intensity aerobic exercise (EX), or a combination of 
intensive reduction of vascular risk factors and exercise (IRVR+EX). We hypothesize that 
both IRVR and EX alone will improve global cognitive function, while the combination, 
IRVR+EX will provide a greater benefit than either IRVR or EX alone.
2.2. Recruitment
Six hundred and forty adults, age 60–85 years are being recruited from the Baton Rouge, 
Dallas, Kansas City, and St. Louis areas where the prevalence rate of CVD is high relative to 
other regions in the U.S. [60, 61]. The rrAD study website (www.rradtrial.org), newsletters, 
social media, and study flyers are being used to raise the awareness of the study among the 
local population and healthcare networks. Each site is also using multiple and diverse means 
of recruitment including print media, local radio station and television, local healthcare and 
research registries, and partnerships with health organizations, e.g., Young Men’s Christian 
Associations (YMCA), insurance organizations, and Alzheimer’s Association chapters. Both 
the existing population within the clinical practice of each site, and individuals from the 
community are used to identify eligible participants. The rrAD study pays special attention 
to raising awareness of the study among local community healthcare networks through an 
outreach program to primary care physicians (PCPs) and other health care professionals. 
This strategy is intended to stimulate patient referral while minimizing potential population 
selection bias and healthy participant effect. The rrAD study strives to include minorities to 
reflect population distributions at each site.
2.3 Inclusion/Exclusion Criteria
The inclusion/exclusion criteria for the rrAD study are based on the principle of maximizing 
the trial external and internal validity by targeting target those who have elevated risk for 
AD. The inclusion criteria are: 1) HTN with a systolic blood pressure (SBP) between 130 
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and 180 mmHg, or SBP between 110 and 130 mmHg when being treated for HTN; 2) 
Subjective memory concerns or having a first degree relative (parent or sibling) with 
diagnosis of dementia, without having significant cognitive impairment themselves (Mini-
Mental State Exam [MMSE] ≥ 26 and no clinical diagnosis of dementia) [62]; 3) Sedentary 
lifestyle (i.e., not meeting the CDC physical activity standard of 30 minutes of moderate 
activity 5 days per week or 20 minutes of vigorous activity 3 days per week) [63], but with 
physical ability to undergo exercise training and/or able to walk at least 10 minutes without 
pain; 4) Fluent in English and adequate visual and auditory acuity to allow 
neuropsychological testing; 5) Have a primary care physician (PCP). The exclusion criteria 
are: 1) Clinically documented history of stroke, focal neurological signs, or other major 
cerebrovascular diseases based on clinical judgment or previous brain imaging; 2) Diagnosis 
of AD or other dementia, or significant neurologic diseases such as Parkinson’s disease, 
seizure disorder, multiple sclerosis, history of severe head trauma, or normal pressure 
hydrocephalus; 3) Evidence of severe major depression (Geriatric Depression Scale [GDS] ≥ 
12) [64] or clinically significant psychopathology, (e.g. psychosis and schizophrenia); 4) 
Unstable heart disease based on clinical judgment (e.g., heart attack/cardiac arrest, cardiac 
bypass procedures within previous 6 months and congestive heart failure), or other severe 
medical conditions; 5) History of atrial fibrillation and evidence on echocardiogram with 
active symptoms of persistent palpitation, dizziness, history of syncope, chest pain, dyspnea, 
orthopnea, shortness of breath at rest, or paroxysmal nocturnal dyspnea within the past 6 
months; 6) resting heart rate (HR) of < 30 or > 110 bpm; taking class I or III anti-arrhythmic 
drugs or clinical concerns for safely participating in exercise and lowering BP; 7) SBP ≥ 180 
mmHg and/or diastolic BP (DBP) ≥ than 110 mmHg; 8) Orthostatic hypotension, defined as 
the third measurement of standing SBP < 100 mmHg after standing from a sitting position; 
9) History of autoimmune disorder (i.e., systemic lupus erythematosus, rheumatoid arthritis 
or polymyalgia rheumatica); 10) Diabetes mellitus with hemoglobin A1C > 7.5% or 
requiring insulin treatment; 12) Regular smoking within the past year; 13) Women with a 
potential for pregnancy, currently pregnant, or lactating; 14) Enrolled in another 
investigational drug or device study, currently or with the past 2 months; 15) Body mass 
index (BMI) >45; 16) allergy to angiotensin receptor blocker or statins; 17) Abnormal 
screening laboratory tests; (e.g., liver function tests [ALT or AST > 3 × ULN], creatine 
phosphokinase > 3 × ULN, estimated glomerular filtration rate < 30 mg/dl or hematocrit < 
28%); 18) Presence of a medical condition limiting estimated survival to < 3 years; 19) Any 
other condition(s) judged by the study investigator to be medically inappropriate, risky, or 
likely to cause poor study compliance.
Approval for this study was obtained from the Human Subjects Committee at Pennington 
Biomedical Research Center (PBRC)-Baton Rouge, The University of Texas Southwestern 
Medical Center and Texas Health Presbyterian Hospital Dallas- Dallas (UTSW/IEEM), 
University of Kansas Medical Center-Kansas City (KUMC), and Washington University 
School of Medicine- St. Louis (WashU).
2.4. Methodological Considerations for Primary Outcome Measures
The primary objective of the study is to determine the independent and combined effects of 
exercise and intensive vascular risk reduction (BP and LDL-C) on neurocognitive function in 
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older adults who have increased risk for developing Alzheimer’s disease. We have chosen 
the ADCS-PACC and the NIH Toolbox Cognition battery because the tests included in these 
batteries have been shown to be sensitive and reliable in detecting age-related cognitive 
decline and have been widely used in studies involving older adults. In addition, systemic 
reviews and meta-analyses of large observational studies and clinical trials have indicated 
that potential effects of physical activity and vascular risk reduction on neurocognitive 
function are manifested primarily in the memory and executive domains which are a focus in 
the ADCS-PACC and NIH Toolbox Cognition battery. Finally, using each of these 
assessment batteries will help ensure the data from the current study will be able to be 
placed in context of the study outcomes in other ongoing trials.
2.5.1 Study assessments
See Table 1 for a complete schedule of all study assessments.
2.5.1. Screening
2.5.1.1. Prescreening: The prescreening questionnaire is completed over the phone or in 
person at a study site upon receiving a phone call or e-mail from a potential participant. 
Prescreening involves explanation of study aims, gathering demographic information, 
collection of a brief medical and medication history, a brief physical activity questionnaire, 
and evaluation of eligibility [63].
2.5.1.2. Screening visits: Following prescreening, suitable individuals are invited to attend 
an informed consent session and two onsite screening visits. The screening assessments are 
divided over two visits and include informed consent, vital signs, electrocardiogram, blood 
collection, physical exam, screening for cognitive impairment and depression, and obtaining 
medical history.
2.5.1.2.1. Vital signs
2.5.1.2.1.1. Sitting heart rate and blood pressure: HR and BP are measured on the right 
arm in a sitting position after resting quietly for at least 5 minutes using a standard 
automated BP device (Welch Allyn Connex® Vital Signs Monitor series 6000). Three 
measurements are performed approximately 1 minute apart. An average of the second and 
third measurements is calculated for data analysis.
2.5.1.2.1.2 Standing heart rate and blood pressure: Participants are asked to stand up to 
measure HR and standing BP. Three sequential measurements are performed immediately 
after the participant stands. Participants are eligible if the SBP remains ≥ 100 mmHg based 
on the third measurement.
2.5.1.2.3. Height, weight and BMI: Participants are asked to remove their shoes for height 
and weight measurements. Height is recorded in cm and weight in kilograms. BMI is 
calculated using the standard equation (kilograms/meter2).
2.5.1.2.4. Demographics, family history, past medical history and current medications: 
Demographic information including birth month and year, sex, race, ethnicity, primary 
Szabo-Reed et al. Page 6
Contemp Clin Trials. Author manuscript; available in PMC 2019 April 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
language, years of education, employment status, profession, marital status, current living 
situation (i.e., independent, assisted, etc.), residence type, zip code, and right or left 
handedness (self-report) is obtained. Family history of parental, sibling and children 
diagnosis of dementia, their age at diagnosis and status (if applicable) are obtained. A 
detailed history of the participant’s current and past medical conditions (including 
cardiovascular disease) is also obtained. Current medications are recorded by participant (or 
significant other) report, current pharmacy action profiles, and verification of medications 
documented in the medical record.
2.5.1.2.5. Screening for cognitive impairment and depression: The participants take the 
MMSE, a commonly used brief screening tool for cognitive impairment [62]. MMSE 
evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, 
and ability to create a sentence and standardized figures. The total MMSE score ranges from 
0 to 30 with a lower score indicative of greater cognitive impairment. Individuals with a 
score of ≥26 are eligible for the study.
2.5.1.2.6. Geriatric Depression Scale (GDS): The GDS (16 item) is used to assess the 
participant’s depressive symptoms. Scores under 11 are eligible for this study. [64].
2.5.1.2.7. Non-fasting clinical blood chemistry: Non-fasting blood samples (~ 10 ml) are 
collected for measurements of hemoglobin A1C, creatine phosphokinase and hematocrit. 
Blood collection and processing procedures and clinical laboratory tests are conducted by 
Quest Diagnostics (Secaucus, NJ), serving as a central clinical chemistry laboratory for the 
rrAD Study.
2.5.1.2.8. Physical/neurological exam and electrocardiogram: A medically qualified 
professional performs a complete physical and neurological exam. A 12-lead 
electrocardiogram is performed and interpreted by a qualified physician to assess the 
presence of cardiac arrhythmia/atrial fibrillation, ischemic cardiac disease, history of 
myocardial infarction and/or left ventricular hypertrophy.
2.5.2. Outcome Assessments—Individuals who complete screening and satisfy all 
inclusion/exclusion criteria are offered the opportunity to participate in the study. A detailed 
timeline of all study assessments is available in Table 1. All baseline assessments are 
completed within 6 weeks prior to randomization. Intervention assessments at 6, 12 and 18 
months are completed within a visit window of two-weeks. End of study assessment (24 
months) are completed within 3 weeks of 24 months from randomization.
2.5.2.1. Neuropsychological testing and questionnaires: Neurocognitive function is 
assessed using the Alzheimer’s Disease Cooperative Study Preclinical Alzheimer Cognitive 
Composite (ADCS-PACC) battery and the NIH-Toolbox Cognition Battery [65, 66]. The 
ADCS-PACC battery [65] consists of the total recall from the Free and Cued Selective 
Reminding test, delayed paragraph recall from the Logical Memory subtest from the 
Wechsler Memory Scale IV, WAIS-R Digit-Symbol Substitution, and the MMSE. The 
ADCS-PACC produces a composite score determined from its components using an 
established normalization method [67]. Each of the 4 component scores is divided by the 
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baseline sample standard deviation of that component to form standardized z-scores, which 
are summed to form the total composite.
The NIH-Toolbox Cognition Battery [66] is an omnibus assessment that tests various 
cognitive domains. The following NIH Toolbox tests are used in rrAD to supplement the 
ADCS-PACC battery: list sorting working memory, flanker inhibitory control and attention 
task, dimensional change card sort test, and pattern comparison processing speed.
Patient Reported Outcomes (PRO) of physical and mental health, cognition and health-
related quality of life are assessed using NIH PROMIS instruments [68, 69]. This 
assessment includes a variety of self-reported questionnaires regarding global health, 
physical function, sleep disturbance, sleep-related impairment, anxiety, depression, anger 
and applied cognitive function. T-scores for each PROMIS domain are used as outcome 
variables, with a mean of 50 (SD=10) in the general population. PRO are measured at 
baseline, 6, 12, 18 and 24 months.
The Cognitive Change Index (20 item) is a self-rating scale of subjective cognitive decline in 
memory and executive over the past 5 years, including the severity of any current problems 
[70]. The neuropsychological tests and questionnaires are completed at baseline, 6, 12, 18 
and 24 months. Every effort is made to schedule participants at the same time of day for all 
testing time points. Participants are instructed to eat and take their normal and study 
medications prior to each assessment.
All neurocognitive testing is performed by trained neuropsychometricians who are required 
to have at least one year of experience with cognitive testing of older adults or approval from 
the investigators. In addition, each psychometrician completes a detailed training and 
scoring procedure that includes at least two supervised test administrations by a site -
identified master tester. Quarterly quality control checks for each study site is performed to 
ensure accurate scoring, and protocols undergo periodic central review, with feedback to 
sites as needed.
2.5.2.2. Fasting Clinical Chemistry: Fasting blood samples (~ 40 ml) are collected after 
overnight fasting (9–12 hours) for measurements of comprehensive metabolic panel and a 
lipid panel. Genetic specimens (DNA and RNA) banking are obtained only from participants 
who consent to this procedure. Whole blood, plasma and serum (~ 30 ml) are aliquoted and 
stored at −80°C for future assays, “omics” data analyses, and long-term storage. Blood 
collection and processing procedures and clinical laboratory tests are conducted by Quest 
Diagnostics. Fasting blood chemistry is collected at baseline, 12 and 24 months.
2.5.2.3 Monitoring for adverse events / Symptom Check: Clinical symptoms associated 
with low BP, such as dizziness, headaches or back pain, are documented at each clinical 
assessment and milestone visit (baseline, 6, 12, 18 and 24 months).
2.5.2.4. Exercise testing/Peak VO2: Exercise testing of peak VO2 with the measurement 
of BP, 12 lead ECG, HR, oxygen uptake is performed: 1) to measure peak VO2; and 2) to 
determine the safety of individual subjects while receiving exercise training. Peak VO2 
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achieved during the test is used as the index of aerobic capacity. It is not expected that all 
participants will be able to achieve ACSM criteria for a VO2max [71]. Following the 
selection of treadmill pace and start grade (baseline only), the test begins at 40–60% of the 
participants HR reserve. Grade is increased 2% per 2 minutes until the participant elects to 
terminate the test, the lead tester evaluates the presence relative or absolute indications for 
test termination or if maximal VO2 criteria have been reached [71]. Maximal effort on the 
test is determined when at least three of the following criteria is achieved: 1) plateau in V02 
(< 100 ml change from last 60 sec. avg. of previous stage) [72, 73]; 2) resting respiratory 
exchange ratio > 1.1; 3) rating of perceived exertion > 17 on 6–20 scale [74], and/or 4) heart 
rate >90% of age-predicted max. Fitness is assessed at baseline, 12 and 24 months.
2.5.2.5. 10 meter walk dual task: The rrAD study uses a 10m walk dual task (walking 
with and without distraction) to assess the subject’s gait velocity and ability to perform two 
simultaneous tasks [75, 76]. Non-distracted gait consists of the average of two timed 10m 
walk times at normal walking speed. Distracted gait consists of asking participants to spell a 
5-letter word backwards while walking at normal walking speed on the same 10m course. 
Scoring includes the average walking time and whether the word was spelled correctly for 
both distracted gait attempts. Dual task is assessed at baseline, 12 and 24 months.
2.5.2.6. Assessment of physical function: The Short Physical Performance Battery 
(SPPB) is used to assess physical function and disability risk [77]. It includes three tasks that 
evaluate lower extremity function: 1) a standing balance task, 2) a gait speed task, and 3) a 
chair rise task. The score for each task ranges from 0–4, and the composite SPPB score is 
based on the sum of the three tasks (range 0–12). Physical function is assessed at baseline, 
12 and 24 months.
2.5.2.7. Assessment of Daily Physical Activity: Yale Physical Activity Survey (YPAS) 
for older adults is a self-reported questionnaire to determine the type, amount and pattern of 
physical activity/exercise in older adults [78]. This survey is used to monitor changes in 
subject’s physical activity in daily life at baseline, 6, 12, 18 and 24 months.
2.5.2.8. Magnetic Resonance Imaging (MRI): MRI measurements of brain structure and 
function are conducted at baseline and at 24 months or before the end of participation. The 
rrAD study adapted the core sequences of the AD Neuroimaging Initiative but with 
optimization [79, 80]. MRI is performed using 3T MRI scanners (UTSW on a Philips 
Achieva scanner and on a GE Discovery MR 750W scanner, KUMC on a Siemens Skyra 
scanner, WashU on a Siemens Prisma scanner, and PBRC on a GE Discovery MR 750W 
scanner). Image quality at each site has been certified by an MRI physicist (DCZ) based on 
both human brain and phantom scans. The sequences used include: 3D T1-weighted high-
resolution images to quantify brain morphometry; T2 fluid-attenuated inversion recovery to 
measure white matter lesions; diffusion tensor imaging to assess brain white matter 
microstructural integrity and structural connectivity; resting-state functional MRI to assess 
neural network functional connectivity; arterial spin labeling to assess brain regional 
cerebral blood flow; T2*-weighted images to detect hemorrhage; and 2D phase contrast 
images to measure arterial blood flow into the brain. Participants are instructed to not 
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consume caffeine within two hours prior to the MRI scan. Total MRI time is approximately 
1 hour per session to minimize participant burden. If MRI data are not usable, the participant 
can be asked to return for a repeat scan.
2.5.3. Staff training and standardization of data collection—Face-to-face 
training sessions were conducted at each study site during site initiation for quality 
assurance and quality control purposes. The rrAD study Clinical Coordinating Center 
(UTSW), the Data Coordinating Center (UTSW), the Biomarker Core (UTSW, and the 
Imaging Coordinating Center (Michigan State University) provide guidelines and technical 
support to all study sites as needed. Each study site organizes training and refresher training 
sessions, including remediation in specific areas targeted by quality control monitoring.
Study personnel performing outcome assessments are blinded to group assignment. The 
rrAD study chief statistician performing primary data analysis is also blinded. Intervention 
staff, site safety officers, and individuals not involved in outcome measures are considered 
unblinded to address safety concerns or adverse events.
2.5.4 Data collection—Data are collected and stored in the Research Electronic Data 
Capture (REDCap), a web-based, electronic data capture tool hosted on a secure, password 
protected, HIPAA-compliant server at UTSW medical center [81]. Case-report-forms 
(CRFs) are entered into the REDCap database using web entry. In addition to sight-
verification, the site study coordinators, the Clinical Coordinating Center (CC), and the Data 
Coordinating Center (DCC) use REDCap’s data quality control module, which reports 
missing values, validation errors, and outliers as well as reports developed by the CC and 
DCC. The Biomarker Core receives blood, plasma, and serum samples from each site with 
unique participant IDs. Biospecimens are shipped in batches to ensure safe receipt, and 
samples are banked upon arrival according the NIA Biospecimen Best Practice Guidelines 
for the Alzheimer’s Disease Centers (https://www.alz.washington.edu/
BiospecimenTaskForce.html). Biospecimens are electronically recorded and all timed 
samples from one participant will be analyzed concurrently to ensure within-participant data 
integrity. Samples are, however, aliquoted in the event assay replicates are needed. All MRI 
data with unique participant IDs are transferred via a secure web-based Globus research data 
management service software (https://www.globus.org/) in DICOM format to the Imaging 
Coordinating Center (ICC) located at the Michigan State University (MSU) within 24 hours 
after the participant is scanned. After receiving the scan information and data from a site, the 
ICC team will complete the data quality control (QC) within three business days. The QC 
ensures (1) that the image data are uploaded to the server appropriately; (2) MRI data match 
participant’s ID, date and protocol parameters; (3) the completeness of the scan; (4) all 
images are transferred with HIPAA-compliant, study-specific identifiers and do not contain 
identifiable participant-specific information; (5) image quality (imaging distortion, artifacts 
and signal-to-noise ratio) for all scans; and (6) run preliminary analyses, such as the 
temporal signal-to-noise ratio and motion parameters for fMRI, to determine if the images 
have sufficient quality for data analysis. The site will be notified if any severe image artifacts 
are found and recommendations will be provided if a participant should be rescanned and/or 
if phantom QC scans should be performed.
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2.6. Randomization
Participants are randomized into one of four study arms stratified by study site, blood 
pressure, age and sex using a constant blocking factor (UC, EXEX, IRVR, and IRVR+EX). 
Randomization assignments are managed centrally using REDCap after all the baseline 
procedures are completed and the participant qualifies for the study.
2.7. Interventions
2.7.1. Usual Care (UC)—Participants in the UC follow their PCP’s recommendations 
for BP and cholesterol control. Participants in this group may or may not be treated with one 
or more pharmacological agents at the initial visit. If SBP is not < 150 mmHg at any time 
point, participant will be asked to visit with their PCP for a BP medication titration.
Instructing participants not to exercise is unethical. Therefore, to encourage study retention 
the investigators will provide all UC and IRVR participants with an optional home-based 
stretching and balance program, as well as access to a stretching and balance program at 
their local YMCA. In the event participants perform the home-based exercises, attend the 
YMCA classes or begin another form of exercise on his or her own, we will assess these 
changes in physical activity using the Yale Physical Activity Survey at baseline, 6, 12, 18 
and 24 months (see Table 1). The home-based stretching program consists of a standardized 
set of nine exercises focused primarily on joint range of motion and flexibility that has been 
implemented in previous RCTs of exercise training [82]. They are instructed to perform the 
stretching and balance exercises 3 times per week and to gradually increase the frequency 
over a period of 3–4 months to 4–5 times per week. Participants are instructed to record the 
number of times and duration per week they perform the stretching and balance exercises on 
a calendar provided by the study staff, which is reviewed monthly by study staff. To enhance 
study retention, participants are also encouraged to attend monthly stretching exercise 
classes hosted by each study site over the 24 months, which are led by study staff or exercise 
trainers. No additional education or support is provided to the UC group beyond the home-
based stretching program and the monthly classes.
2.7.2. Aerobic Exercise (EX)—Participants in EX only arm follow their PCP’s 
recommendations for BP and cholesterol management as in the UC group. In addition, they 
perform a structured, moderate-to-vigorous aerobic exercise training and supervised by 
exercise professionals at local exercise facilities. Each study site is at liberty to engage with 
community facilities or use their own exercise facility to conduct the training. Identified 
facilities have appropriate safety protocols and exercise trainers with nationally-recognized 
certification (e.g., ACSM, ACE) or appropriate education (exercise physiology degree, 
clinical licensure, etc.). Each study site follows the direction of their IRB as to what and how 
facilities are approved for use. Figure 1 shows the template for rrAD EX training by week 
during the intervention period. An exercise training log, safety tips, and instructions for 
using a HR monitor is provided to participants at the first orientation visit. The first 
orientation visit also includes the first in-person training session to instruct participants in 
proper exercise intensity for their physical fitness levels. Treadmill walking or jogging, 
cycling, stepping (including recumbent), and similar aerobic modalities are acceptable.
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During Weeks 1–4, all participants receiving the EX intervention are supervised by a trainer 
for every session (3 times per week). Trainers fit participants with a HR monitor and help 
participants to exercise in the appropriate target HR zone and at the associated Borg Rating 
of Perceived Exertion (RPE; 6–20) [74]. Trainers help participants understand what training 
HR zones are associated with what perceived exertion levels during weeks 1–4, so that when 
the participants begin to exercise independently, they can appropriately adjust their work rate 
based on perceived exertion rather than target HR zone. Trainers ask participants their RPE 
every 5–10 minutes while monitoring HR and teach the participants to adjust intensity 
accordingly by speed, grade, resistance, etc. as appropriate. Trainers instruct participants 
how to appropriately warm-up and cool-down at least 5 minutes at every session. 
Participants are instructed to engage in structured aerobic physical activity 3 or more times 
per week to complete the minimal requirement of prescribed weekly exercise duration.
Per Figure 1, intensity gradually increases over the first 3 months of the study to allow 
participants to gradually and safely adapt to exercise. Exercise logs given to each participant 
have information on target effort and target HR zone for each month of exercise. The 
exercise program is prescribed individually, based on the maximal HR obtained during peak 
VO2 testing at baseline. At the beginning of the study, participants exercise at a light-to-
moderate intensity, an RPE of 10–12 or 55–65% of HRmax. By Week 5 participants begin to 
exercise at a moderate intensity, an RPE of 12–14 or 65–75% of HRmax. By Week 9, 
participants are encouraged to gradually incorporate more vigorous levels of exercise as able 
with support and supervision of their trainer, including RPE of 14–17 or 65–85% of HRmax.
Exercise duration or volume is gradually increased over the first 6 months. By Month 6, all 
participants receiving the EX intervention are expected to achieve the goal of 160 minutes of 
moderate-to-vigorous aerobic exercise per week at the prescribed intensity, including ~ 5 
minutes warm-up and cool-down periods at each exercise session. This goal was selected to 
encourage participants to meet or exceed public health recommendations [71]. Participants 
unable to exercise continuously will perform intermittent bouts (minimum 10 min each) 
until the target is reached. During Weeks 5–12, participants are supervised at least 1 session 
per week. Beginning at Week 13, participants are allowed to exercise at home or at another 
training location, if the trainer and/or certified study staff confirm that participants are able 
to judge their exercise intensity with RPE. Participants are instructed to work with their 
trainer at least 1 session per month for the duration of the 24-month intervention period. The 
participant is expected to record the duration of exercise (not including warm up and cool 
down) and their overall judgment of RPE in an exercise log at every exercise session. Study 
staff regularly check these logs at least once per month for protocol compliance. Adherence 
is measured as the percentage of total minutes per week of prescribed exercise.
2.7.3. Intensive Reduction of Vascular Risk Factors (IRVR)—Participants in the 
IRVR group follow the rrAD BP and cholesterol lowering algorithms for treatment of 
hypertension and hypercholesterolemia (Figure 2). Individuals randomized to this group also 
receive the home-based stretching and balance exercise program as in UC group to account 
for potential “placebo” effects of aerobic exercise training as described in section 2.7.1. At 
the first orientation/vascular clinic visit, a 30–90-day supply of study medication (the 
amount of drug dispensing will be site specific) and a brochure about the study medication, 
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safety tips, and instructions for taking study medications is provided to the participants. 
Potential drug-drug interactions and adjustment or replacement of current BP or cholesterol 
lowering medications (if they are taking any) is discussed with the participants and any 
questions are addressed before the initiation of drug therapy. As for the UC group, 
instructions for performing stretching and balance training properly, safety tips, and a 
stretching and balance training log, are provided at the first orientation visit.
The rrAD study uses an evidence-based protocol to lower SBP (goal < 130 mmHg) and 
cholesterol (goal LDL-C < 70 mg/dL)(Figure 2)[35, 83, 84]. Calcium channel blocker 
(CCB) amlodipine and angiotensin II receptor blocker (ARB) losartan are the first line 
antihypertensives for IRVR group because of their effectiveness in reducing BP and 
reduction in CVD risk and safety in large clinical trials [84–86]. Low dose thiazide diuretic 
chlorthalidone, potassium-sparing diuretic spironolactone, or alpha 1-adrenergic receptor 
inhibitor doxazosin will be added if needed to reach the BP goal. For participants already 
being treated for hypertension with SBP of 110 to 130, their antihypertensives will be 
replaced with amlodipine and losartan to maintain or achieve a SBP < 130 mmHg if 
applicable based on a clinical assessment.
For treating hypercholesterolemia, atorvastatin 80mg daily is used for the IRVR participants 
with a fasting LDL-C ≥ 70 mg/dL. For individuals who have LDL-C < 70 mg/dL, and are 
not on any statins, atorvastatin is not initiated. Those with LDL-C < 70 mg/dL on a statin, 
their statin is switched to atorvastatin with an equivalent dose as the current statin if 
applicable based on a clinical assessment. Figure 2 describes the detailed algorithm for 
cholesterol management. The study clinician may adjust the dose, stop or change anti-
hypertensives to reach SBP goal of < 130 mmHg in the interest of participant safety. Once 
the SBP goal is achieved, the anti-hypertensive regimen may be intensified further if DBP 
remains ≥ 100 mmHg at a single visit or ≥ 90 mm Hg at two successive visits.
Medication adjustments are made on an individual basis if a participant develops side 
effects. For example, if a participant develops myalgias or elevation in CPK, the atorvastatin 
dose may be reduced or stopped depending on the severity of the side effects. Study 
medication may be restarted after the associated side effects are reduced or adequately 
addressed. Once randomized, if a participant is no longer able to continue with the study, 
he/she may be followed for intent-to-treat purposes.
2.7.4. IRVR+EX—Participants in the IRVR+EX group follow the BP and cholesterol 
lowering algorithm as well as the structured aerobic exercise training program, as described 
above.
2.7.5. Intervention compliance and adherence monitoring—Participants are 
encouraged to stay with the intervention/s they are randomized to. However, potential 
changes in lifestyle or other health-related behaviors may occur (e.g., participants in the UC 
or the IRVR group may start aerobic exercise). Any changes in the health-related behavior or 
medication, which may impact study outcome, are reviewed, discussed and documented 
during regular study visits.
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Treatment effects of BP lowering are monitored at each study visit. Participants are asked to 
return study medications and bottles, used and unused, at each visit. Pill counts are 
performed to calculate percentage of pills taken/dispensed to document drug adherence in 
the IRVR and IRVR+EX groups. Exercise adherence is recorded as the percentage of the 
total number of minutes exercised (recorded in log) per week relative to the number 
prescribed in the EX and IRVR+EX groups. The rrAD study goal is >80% treatment 
adherence for both IRVR and EX interventions. Potential effects of intervention adherence 
on study outcome measures will be assessed as secondary data analysis.
Monthly phone or in-person follow-up and three-month clinic visits to monitor study safety 
and compliance are conducted with all participants to maintain a same level of study contact 
across the study groups. At each visit, participants are asked about any changes in their 
health or medications to monitor potential influences on study outcome measures.
2.8. Strategies for participant retention
Every effort is made to provide a friendly clinic environment for study visits, foster personal 
relationships between study staff and participants, and minimize study burden. Written 
instructions for follow-up visits are provided to participants and reminder calls are made 
before each study visit to increase attendance. Exercise training programs and locations are 
flexible to fit each participant’s needs and preferences. Alterations in exercise mode, 
duration, or intensity are made as necessary to maintain the overall training pattern and 
“dose” among participants and across study sites. Time constraints and medical conditions 
can hinder exercise patterns in older adults. If participation falls below target (i.e., 80%), site 
staff or the exercise trainer works with the participant to identify barriers and increase 
adherence. Strategies are employed to help the participants overcome these barriers to 
adherence (i.e., planning a schedule, changing exercise modes if injured, etc.). Exercise 
training may be restarted after an interruption due to medical or other personal issues. These 
and other strategies such as goal setting, positive reinforcement, self-monitoring, regular 
follow-up, and motivational interviewing, are used to enhance study adherence. Retention 
strategies are also employed if a participant is not compliant with their IRVR study visits or 
medication.
Similar to interventions to increase adherence with exercise, study staff work with 
participants to develop personalized strategies to encourage visit attendance and medication 
adherence. Each of the 4 sites has experience in successfully conducting exercise and 
pharmocological studies in the elderly and will utilize different approaches that have proven 
to work well in the past at each site. The overarching theme to these approaches is to provide 
a “customer service” approach that continually focuses on reducing participant burden as 
much as possible, addressing participant questions and concerns in a rapid manner, and 
maintaining as much uniformity and consistency as possible in terms of interactions with the 
participant. Examples include trying to maintain continuity of coordinator-participant 
interactions, providing sufficient lead time and reminders for scheduled visits, and promptly 
responding the emails and/or phone calls from the participant. In addition, study sites will be 
hosting thank you events for study participants and the rrAD study provides a modest 
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stipend every 6 months for all participants, following the completion of each outcome 
assessment visit (See Table 1.).
2.9. Sample size estimation and data analysis plan
2.9.1. Sample size estimation—The rrAD study is designed to detect changes in 
neurocognitive function among the intervention groups and to test the central hypothesis that 
benefits of IRVR+EX on improving global neurocognitive function is greater than those of 
UC, IRVR alone, or EX alone. The composite z score of global cognition will be obtained 
by conversion of individual test scores to the standardized z scores, then averaged to obtain a 
composite score. Confirmatory factor analysis (CFA) will be used to validate the proposed 
domain-specific and global cognition scores. Sample size and power estimates were 
conducted using a linear mixed models analysis of variance (ANOVA) design estimating 
effect size using Cohen’s d for the interaction of EX by IRVR combinations. Several 
covariance structures (AR (1)), compound symmetry, unstructured, etc.) for the repeated 
measures were considered with time points of 5, 3 and 2. Table 2 presents the results of 
sample size and power estimates based on the covariance structure of compound symmetry. 
For primary outcome of global neurocognitive function (5-time points over 2 years), with a 
correlation of 0.5 between repeated measures and an alpha level of 0.05, group sample sizes 
of 128 in each of EX by IRVR combinations (accounts for a potential 20% dropout rate) will 
achieve 82.4% power to detect a standardized difference of d=0.28 in changes in global 
neurocognitive function between the IRVR + EX and the UC group (2 × 2 factorial design).
2.9.2. Analysis plan
2.9.2.1. General considerations: Baseline and demographic characteristics will be 
summarized overall and by treatment group. Summaries will be provided for continuous and 
categorical measures. All measures will be screened for outliers and transformation may be 
performed to normalize the data, if necessary. Residual and multicollinearity diagnostics will 
be performed to assess model assumption. Unless otherwise noted, all tests of treatment 
effects and interactions will be conducted at a 2-sided alpha level of 0.05; 2-sided 
confidence intervals will be displayed with a 95% confidence level. The primary analysis 
consists of a linear mixed model with the interaction terms of treatments and time as the 
primary predictor variables. We assume that changes in global cognitive function over 2-yrs 
will be linear and this assumption will be confirmed with plots of individual growth curves. 
All analyses will follow the modified intent-to-treat (mITT) principle unless otherwise 
specified [87]. An ITT analysis is an analysis of data by groups to which the subjects are 
assigned by random allocation, even if the subject does not take the assigned treatment, does 
not receive the correct treatment, or otherwise does not follow the protocol. A mITT analysis 
is an ITT analysis for all participants who have a baseline and at least 1 post baseline 
measure. Secondary analyses will consist of adjustments for potential effects of covariates 
on outcome measures such as baseline cognitive score, APOE4 genotype, peak VO2, and 
treatment effects of BP and lipids to reveal a potential “dose-response” relationship.
2.9.2.2. Safety Mornitoring and DSMB: Potential side effects of antihypertensive and 
atorvastatin will be reviewed and discussed with participants during the enrollment. 
Participants will be asked to inform the study clinician or staff immediately if side effects 
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occur and persist. Participants will be monitored and interviewed during each of the follow-
up visits to ensure that any symptoms are addressed early and properly. The rrAD data safety 
and monitoring board (DSMB) will review and approve the study protocol including the 
plan for safety monitoring and reporting. DSMB will also monitor the study data integrity 
and any adverse effects which may occur during the study, and evaluate the progress of the 
trial, including assessments of data quality, timeline of recruitment and accrual, retention, 
participant risk versus benefit, performance of the trial sites, and other factors that can 
influence study progression and outcome. The DSMB will receive safety report quarterly 
and meet every six months with rrAD investigators to monitor study safety and progress, 
advise the NIH about the study performance, and make recommendations regarding study 
continuation and protocol changes.
2.9.2.3. Interim analysis: The medications and supervised aerobic exercise training used 
in the rrAD study are widely used clinical interventions to improve cardiovascular health in 
older adults. However, the benefits of these interventions on neurocognitive function have 
not been demonstrated conclusively, and the potential effect size is likely to be small to 
moderate based on observational studies and meta-analysis of a few of small RCTs. In 
addition, the benefits of these interventions on brain structure and function, if they manifest, 
are likely cumulative over time. Considering the potential moderate effects of the rrAD 
study on neurocognitive function, the study team has decided not to conduct an interim 
efficacy analysis. However, the rrAD study DSMB may require an interim safety data 
analysis based on overall safety profile, work-in-progress report, adverse event or serious 
adverse event monitoring.
2.9.2.4. Missing data: The MRI involves two assessments, one at baseline and one at 24 
months, thus limiting the range of analytic strategies. We plan to use a maximum likelihood 
based general linear models for analyzing imaging outcomes [88]. Intracranial volume will 
be included as a covariate. The validity of the Missing at Random assumption will be 
examined and baseline measurements will be included as covariates for modeling and data 
analysis. If loss to follow-up is related to the unobserved cognitive outcome then our results 
may be biased. Again, modeling assumptions and sensitivity analysis may be considered if 
necessary. mITT and ITT analysis will be used to handle all behavior and other missing data.
3. Discussion
The rrAD study is vital to providing clinicians, public health organizations, and policy 
makers information on independent and combined importance of IRVR and EX treatments. 
rrAD is the first study utilizing a 2 × 2 factorial design to determine both the independent 
and combined effects of EX and IRVR on neurocognitive function and AD biomarkers in 
older adults who are at high risk for AD [38, 89]. Using an integrated systems approach, this 
project aims to reduce several age-related co-morbidities (hypertension, 
hypercholesterolemia, and physical inactivity) simultaneously to achieve maximal gain to 
improve brain health in older adults. In addition, the selected design is potentially 
deployable as it can utilize community physicians and health resources to deliver the IRVR 
and EX treatments.
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The rrAD study will also be the first study using state-of-the-art neuroimaging and blood 
biomarkers along with detailed neurocognitive measures to determine the independent and 
combined effects of EX and IRVR on brain pathophysiological changes related to AD. 
Extensive studies have previously reported that hypertension, elevated cholesterol and/or 
physical inactivity are associated with brain atrophy, white matter hyperintensities and brain 
amyloid burden in older adults [90–93]. rrAD will provide direct evidence whether the 
proposed interventions alter the trajectory of brain pathophysiological changes, and whether 
IRVR+EX has greater impacts than IRVR or EX alone on brain structure and function, thus 
indicating a potential cause-effect relationship between the presence of vascular risk factors 
and brain pathophysiology.
Finally, evidence from rrAD will have immediate implications for target BP levels and 
intensity of cholesterol management to prevent cognitive decline in older adults. Our 
approach for vascular risk reduction will serve as the standard (e.g., the medications to be 
used, treatment effect, and safety evaluations) for future AD prevention trials. If rrAD 
interventions are proven to be practical and successful, our study may lead to revision of the 
guidelines to intensify cardiovascular risk factor control for prevention of AD in older 
adults.
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Abbreviations:
Aβ Amyloid-Beta
AD Alzheimer’s Disease
ADCS-PACC Alzheimer’s Disease Cooperative Study Preclinical Alzheimer 
Cognitive Composite
BP Blood Pressure
CVD Cardiovascular disease
FLAIR fluid-attenuated inversion recovery
EX Aerobic exercise
HR Heart rate
HTN hypertension
KUMC University of Kansas Medical Center
LDL-C Low-density lipoprotein cholesterol
IRVR = Intensive Pharmacological Reduction in Vascular Risk
mITT modified intent-to-treat
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MRI Magnetic Resonance Imaging
NIRS near infrared spectroscopy
PBRC Pennington Biomedical Research Center
PCP Primary Care Physician
PRO Patient Reported Outcomes of physical and mental health
RCT Randomized controlled trial
rrAD Risk Reduction for Alzeimer’s Disease
UC Usual Care
UTSW University of Texas Southwestern Medical Center
WashU Washington University Medical Center
YMCA Young Men’s Christian Associations
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Figure 1. 
rrAD Study Aerobic Exercise Training Schedule
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Figure 2. 
Cholesterol Management in IRVR and IRVR + EX
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Table 1.
Study Assessments
Prescreening In Person Screening Baseline 6 Months 12 Months 18 Months 24 
Months/
End of 
Study
Prescreening questionnaire X
Informed Consent X
BP Measurement X
MMSE X X X X
Demographics X
Family History X
Health History X
Medications X
GDS X
Non-Fasting Clinical Blood 
Chemistry
X
Physical Exam X
ECG X
FAQ X X X
Neurocognitive Assessments X X X X X
Fasting Blood Chemistry X X X
Symptoms Check X X X X X
Exercise Test X X X
SPPB/Dual Task X X X
Yale Physical Activity Survey X X X X X
MRI X X
TCD X X X
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Table 2.
Sample size and power estimations*
Time points Cohen’s d Correlation Power
5 0.16 0 >81.6%
5 0.24 0, 0.3 >82.4%
5 0.28 0, 0.3, 0.5 >82.4%
5 0.31 0, 0.3, 0.5, 0.7 >81.1%
3 0.21 0 >82.8%
3 0.26 0, 0.3 >81.2%
3 0.29 0, 0.3, 0.5 >81.0%
3 0.32 0, 0.3, 0.5, 0.7 >81.6%
2 0.25 0 >80.7%
2 0.29 0, 0.3 >82.0%
2 0.31 0, 0.3, 0.5 >81.6%
2 0.33 0, 0.3, 0.5, 0.7 >81.6%
*
Alpha=0.05; N=128/group; compound symmetry.
Contemp Clin Trials. Author manuscript; available in PMC 2019 April 01.
